Navigation Links
SeraCare Life Sciences Appoints Sean O'Connor as Vice President of Sales and Marketing
Date:3/17/2011

MILFORD, Mass., March 17, 2011 /PRNewswire/ -- SeraCare Life Sciences, Inc. (Nasdaq: SRLS), a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, today announced the appointment of Sean O'Connor as Vice President of Sales and Marketing.  In this position, Mr. O'Connor will be responsible for aligning and optimizing all sales and marketing operations at SeraCare.

"Sean's leadership and experience in driving high growth in life sciences sales organizations are the exact skill set that SeraCare sought when we made the strategic decision to comprehensively upgrade our sales and marketing capabilities," said Susan Vogt, President and Chief Executive Officer. "His extensive sector-specific knowledge, strong strategic planning skills and proven ability to grow business revenues will be instrumental as we seek to increase the scope and size of our customer base."

"SeraCare is an exceptional player in the life science sector with a robust catalog of profitable offerings, a loyal customer base and tremendous growth opportunities. I look forward to contributing to the achievement of the aggressive sales objectives that we have already set," commented Mr. O'Connor. "I believe these goals can be met by expanding the geographic reach of our customer base, enhancing service to existing customers and continuing to explore new markets for our diverse catalog of best-in-class products."

Mr. O'Connor brings over twenty years of experience in sales and marketing management in the life sciences and diagnostic industry to SeraCare. He has held positions of increasing responsibility at Ortho Clinical Diagnostics, a Johnson & Johnson Company, including over fifteen years in management level positions. Most recently Mr. O'Connor was Director, Strategic Accounts, a position in which he consistently and significantly grew revenues while creating new channel opportunities, including generating growth in revenue from the reference lab market. Mr. O'Connor is a graduate of Emporia State University and was also accepted to and completed the Kauffman Foundation's FastTrac TechVenture™ Program.

About SeraCare Life Sciences, Inc.SeraCare serves the global life sciences industry by providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics. The Company's innovative portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers, biobanking and contract research services. SeraCare's quality systems, scientific expertise and state-of-the-art facilities support its customers in meeting the stringent requirements of the highly regulated life sciences industry.

Forward-Looking Statements:This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about SeraCare Life Sciences, Inc. ("SeraCare" or the "Company"). All statements regarding our expected future financial position, results of operations, cash flows, dividends, financing plans, business strategy, budget, projected costs or cost savings, capital expenditures, competitive positions, growth opportunities for existing products or products under development, plans and objectives of management for future operations and markets for stock are forward-looking statements. In addition, forward-looking statements include statements in which we use words such as "expect," "believe," "anticipate," "intend," or similar expressions. Although we believe the expectations reflected in such forward-looking statements are based on reasonable assumptions, we cannot assure you that these expectations will prove to have been correct, and actual results may differ materially from those reflected in the forward-looking statements. Factors that could cause our actual results to differ from the expectations reflected in the forward-looking statements in this press release include, but are not limited to, failure to maintain proper inventory levels, availability of financing, reductions or terminations of government or other contracts, interruption in our supply of products or raw materials, actions of SeraCare's competitors, changes in the regulatory environment, delays in new product introductions, lack of market acceptance of new products, decreased healthcare spending, reduced margins resulting from a shift in revenue towards services, prolonged impairment of sales from changes in our sales organization, absence or loss of acquisition opportunities to higher bidders, potential failure to complete any announced acquisition, and potential failure of any acquisition to produce expected revenues, profits or synergies. Many of these factors are beyond our ability to control or predict.Contacts:Gregory A. GouldChief Financial OfficerSeraCare Life Sciences, Inc.508-244-6400Sarah CavanaughMacDougall Biomedical Communications781-235-3060
'/>"/>

SOURCE SeraCare Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SeraCare Reports First Quarter Fiscal Year 2011 Results
2. SeraCare Life Sciences to Report First Quarter 2011 Financial Results on February 11, 2011
3. SeraCare Life Sciences Secures $20 Million Credit Facilities
4. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
5. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
6. Life Technologies to Webcast Investor Presentation as Part of the UBS West Coast Life Sciences & Diagnostics Bus Trip
7. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
8. Swift Biosciences Presents Highly Sensitive, Highly Specific qPCR Mutation Detection Data at 18th International Molecular Medicine Tri-Conference
9. Martek Biosciences Inducted into Small Business Innovation Research (SBIR) Hall of Fame
10. Georgia Health Sciences University Clinical Study Shows RyMed InVision-Plus® IV Connector Significantly Decreased Central Venous Catheter Occlusions in Oncology Patients
11. Transgenomic to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on February 17
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... monitoring solutions, today announced the hire of Dr. Sigmund “Sig” Floyd as Vice ... applications, strategic partnerships and joint development activities. , “Dr. Floyd’s career has spanned ...
(Date:3/22/2017)...  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical ... address significant unmet medical needs in rare diseases, ... ended December 31, 2016. "2016 ... we broadened our pipeline and pursued our vision ... with an initial focus on endocrinology," said ...
(Date:3/22/2017)... JERUSALEM , March 22, 2017 ... ( www.oramed.com ), ... of oral drug delivery systems, announced today that ... Officer, will deliver a presentation titled, "Oral Insulin ... upcoming Cambridge Healthtech Institute,s Oligonucleotide and Peptide Therapeutics ...
(Date:3/22/2017)... Florida , March 22, 2017 ... ... various cancer conditions are being pressured as of late due ... for cancer pain management has a dramatic impact on patient,s ... research and development activities for identifying new forms of opioid ...
Breaking Biology Technology:
(Date:3/2/2017)... Who risk to be deprived of its imprint in ... https://www.reportbuyer.com/product/4313699/ WILL APPLE AND SAMSUNG CONFRONT EACH ... using capacitive technology represent a fast growing market, especially ... increase of 360% of the number of fingerprint sensor ... market between 2014 and 2017 (source : N+1 Singer, ...
(Date:2/28/2017)...  EyeLock LLC, ein marktführendes Unternehmen im Bereich ... Lösung zur Iris-Erkennung auf der neuesten Mobilplattform ... dem Mobile World Congress 2017 (27. Februar ... 3, Stand 3E10, vorstellen. Der ... – eine Kombination aus Hardware, Software und ...
(Date:2/21/2017)... and PORTLAND, Ore. , Feb. ... the Avamere Family of Companies (Avamere Health Services, Infinity ... a six-month research study that will apply the power ... at senior living and health centers. By analyzing data ... to gain insights into physical and environmental conditions, and ...
Breaking Biology News(10 mins):